Anti-CGRP Migraine Drugs Cut Monthly Headache Days by Nearly Half in Catalan Cohort
A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.
A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.
Here we go…Frexalimab to inhibit progressive MS?. Frexalimab is a CD40Ligand blocking antibody for development in MS. Frexalimab inhibits relapsing and progressive MS, so they say,...
The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or without inhibitors — has been approved in the European Union...
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1
Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...
Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.